Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
In: Penngton KP, Walsh T, Lee M, Penn C, Novetsky AP, Agnew KJ, Thornton A, Garc R, Mutch D, Kg MC, Goodfellow P, Swher EM. BRCA1, TP53, and CHEK2 germle mutatns utere serous carcoma. Cancer. 2013 Jan 15;119(2):332-8. do 10.1002/cncr.27720. Epub 2012 Jul 18. Frer M, Levano KS, Rodruez-Gab A, Wang Y, Goldberg GL, Horwz SB, Hou JY. Germle mutatns of the DNA repa pathways utere serous carcoma. Gynecol Oncol. 2016 Apr;141(1):101-7. do 10.1016/j.ygyno.2015.12.034. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Chernck AD, AkbanR, L Y, Shen H, Robertson AG, Pashtan Shen R, Benz CC, Yau C, Lad PW, Dg L, Zhang W, Mls GB, KucherlapatR, Mard ER, Leve DA. tegrated genom characteratn of endometrl carcoma. Nature. 2013 May 2;497(7447):67-73. do 10.1038/nature12113. Erratum : Nature. 2013 Aug 8;500(7461):242. Shu CA, Pe MC, JotwanAR, Frbel TM, Soslow RA, Leve DA, Nathanson KL, Konner JA, Arnold AG, Bogomoln F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leao MM Jr, Abu-Rustum NR, Aghajann CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, aacs C, Eeles RA, Ganz PA, Barakat RR, Off K, Domchek SM, Rebbeck TR, Kauff ND. Utere Cancer After Rk-Reducg Salpgo-oophorectomy Whout Hysterectomy Women Wh BRCA Mutatns. JAMA Oncol. 2016 Nov 1;2(11):1434-1440. do 10.1001/jamaoncol.2016.1820. de Jonge MM, Mooyaart AL, Vreeswk MP, de Kroon CD, van Wezel T, van Asperen CJ, Sm VT, Dekkers OM, Bosse T. Lkg utere serous carcoma to BRCA1/2-assocted cancer syndrome: A meta-analys and case report. Eur J Cancer. 2017 Feb;72:215-225. do 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31. Mza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote Ben-Baruch NE, Marth C, Madry R, Chrtensen RD, Berek JS, Dorum A, Tker AV, du Bo A, Gonzalez-Mart A, Follana P, Benno B, Rosenberg P, Gbert L, Rel BJ, Buscema J, Balser JP, Agarwal S, Matulon UA; ENGOT-OV16/NOVA vestators. Napar Matenance Therapy Platum-Sense, Recurrent Ovarn Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. do 10.1056/NEJMoa1611310. Epub 2016 Oct 7. Swher EM, L KK, Oza AM, Scott CL, Grdano H, Sun J, Konecny GE, Coleman RL, Tker AV, O'Malley DM, Krtele RS, Ma L, Bell-McGun KM, Brenton JD, Cragun JM, Oakn A, Ray-Coquard Harrell M Mann E, Kaufmann SH, Floquet A, Leary A, Hardg TC, Goble S, Maloney L, aacson J, Allen AR, Rolfe L, Yelensky R, RaponM, McNeh Rucapar relapsed, platum-sense hh-grade ovarn carcoma (ARL2 Part 1): an ternatnal, multentre, open-label, phase 2 trl. Lancet Oncol. 2017 Jan;18(1):75-87. do 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29. Trial of Maintenance With Niraparib in Patients With Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma
Online
report
| Titel: |
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
|
|---|---|
| Autor/in / Beteiligte Person: | Tesaro, Inc. ; Marina Frimer, Principle Investigator |
| Link: | |
| Quelle: | Penngton KP, Walsh T, Lee M, Penn C, Novetsky AP, Agnew KJ, Thornton A, Garc R, Mutch D, Kg MC, Goodfellow P, Swher EM. BRCA1, TP53, and CHEK2 germle mutatns utere serous carcoma. Cancer. 2013 Jan 15;119(2):332-8. do 10.1002/cncr.27720. Epub 2012 Jul 18. Frer M, Levano KS, Rodruez-Gab A, Wang Y, Goldberg GL, Horwz SB, Hou JY. Germle mutatns of the DNA repa pathways utere serous carcoma. Gynecol Oncol. 2016 Apr;141(1):101-7. do 10.1016/j.ygyno.2015.12.034. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Chernck AD, AkbanR, L Y, Shen H, Robertson AG, Pashtan Shen R, Benz CC, Yau C, Lad PW, Dg L, Zhang W, Mls GB, KucherlapatR, Mard ER, Leve DA. tegrated genom characteratn of endometrl carcoma. Nature. 2013 May 2;497(7447):67-73. do 10.1038/nature12113. Erratum : Nature. 2013 Aug 8;500(7461):242. Shu CA, Pe MC, JotwanAR, Frbel TM, Soslow RA, Leve DA, Nathanson KL, Konner JA, Arnold AG, Bogomoln F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leao MM Jr, Abu-Rustum NR, Aghajann CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, aacs C, Eeles RA, Ganz PA, Barakat RR, Off K, Domchek SM, Rebbeck TR, Kauff ND. Utere Cancer After Rk-Reducg Salpgo-oophorectomy Whout Hysterectomy Women Wh BRCA Mutatns. JAMA Oncol. 2016 Nov 1;2(11):1434-1440. do 10.1001/jamaoncol.2016.1820. de Jonge MM, Mooyaart AL, Vreeswk MP, de Kroon CD, van Wezel T, van Asperen CJ, Sm VT, Dekkers OM, Bosse T. Lkg utere serous carcoma to BRCA1/2-assocted cancer syndrome: A meta-analys and case report. Eur J Cancer. 2017 Feb;72:215-225. do 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31. Mza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote Ben-Baruch NE, Marth C, Madry R, Chrtensen RD, Berek JS, Dorum A, Tker AV, du Bo A, Gonzalez-Mart A, Follana P, Benno B, Rosenberg P, Gbert L, Rel BJ, Buscema J, Balser JP, Agarwal S, Matulon UA; ENGOT-OV16/NOVA vestators. Napar Matenance Therapy Platum-Sense, Recurrent Ovarn Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. do 10.1056/NEJMoa1611310. Epub 2016 Oct 7. Swher EM, L KK, Oza AM, Scott CL, Grdano H, Sun J, Konecny GE, Coleman RL, Tker AV, O'Malley DM, Krtele RS, Ma L, Bell-McGun KM, Brenton JD, Cragun JM, Oakn A, Ray-Coquard Harrell M Mann E, Kaufmann SH, Floquet A, Leary A, Hardg TC, Goble S, Maloney L, aacson J, Allen AR, Rolfe L, Yelensky R, RaponM, McNeh Rucapar relapsed, platum-sense hh-grade ovarn carcoma (ARL2 Part 1): an ternatnal, multentre, open-label, phase 2 trl. Lancet Oncol. 2017 Jan;18(1):75-87. do 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29. Trial of Maintenance With Niraparib in Patients With Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma |
| Medientyp: | report |
| Sonstiges: |
|